Cite
HARVARD Citation
Wang, J. et al. (n.d.). Preliminary results from HERKULES-1: a phase 1b/2, open-label, multicenter study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors. European journal of cancer. pp. S80-S81. [Online].